Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Rocket Lab Corporation announced the launch of GHOST, a globally deployable, containerized launch system that enables rapid suborbital and orbital launches from anywhere worldwide. The system supports their Electron and HASTE rockets, allowing quick deployment and simultaneous multi-launch campaigns, particularly targeting national security and mis…
Agomab Therapeutics NV announced the proposed appointments of Marino Garcia and Dr. Naimish Patel to its Board of Directors, aiming to strengthen governance with their extensive biotech and clinical development expertise. The appointments will be voted on by shareholders at a special meeting in September 2026. The company also plans to adjust pre-I…
Rocket Lab announced a contract to launch a dedicated Neutron rocket mission for Kepler Communications, deploying multiple satellites to low Earth orbit starting in 2028. This is Kepler's first time booking a dedicated commercial launch vehicle, allowing greater control over launch schedule and orbital parameters to support their expanding constell…
Getty Images reported Q2 2026 revenue of $229.1 million, down 2.5% year-over-year, with a net loss of $85.8 million compared to $34.4 million the prior year. Despite growth in editorial revenue and increased annual subscription revenue percentage, pressures in agency and iStock segments persist. The company faces increased tax expenses and interest…
Public Policy Holding Company, Inc. announced its Q2 2026 financial results featuring 16.3% year-over-year revenue growth in the first half of 2026, driven by organic growth and earnings-accretive acquisitions. The company completed multiple acquisitions to diversify services and strengthen its presence in strategic communications across the U.S. a…
Alico, Inc. announced its Q3 2026 financial results showing a net income of $2.1 million, a substantial improvement from a net loss in the prior year quarter, driven by its ongoing strategic transformation shifting focus from citrus production to land leasing, sales, and development. The company signed a new agricultural lease for 3,280 acres with …
CeriBell, Inc., a US-based medical technology company specializing in neurological diagnostic tools, reported a 33% increase in total revenue for Q2 2026 compared to Q2 2025, driven by growth in new and existing accounts. The company achieved a 92% gross margin, secured multiple FDA 510(k) clearances for new algorithms and hardware, and obtained Ne…
Tactile Systems Technology, Inc. reported its Q2 2026 financial results showing a 9% year-over-year revenue increase to $85.7 million and net income more than doubling to $7.8 million. The company expanded gross margins to 76%, launched new products including the next-generation AffloVest system, and entered an exclusive U.S. distribution deal for …
Playboy, Inc. announced solid second quarter 2026 financial results, highlighted by 11% revenue growth to $31.2 million driven by Honey Birdette's 18.2% sales increase, a return to net income of $0.2 million compared to a prior year loss, and a doubling of adjusted EBITDA to $7.0 million. The company also initiated a significant share repurchase an…
Vera Therapeutics announced FDA accelerated approval for TRUTAKNA, the first and only therapy targeting BAFF and APRIL to treat adults with primary IgA nephropathy (IgAN) at risk for disease progression. The company has launched commercial U.S. sales, aligned with the FDA to pursue potential full approval pending ORIGIN 3 trial results expected in …
Ticketplus Ltd., a Chile-based technology platform specializing in live entertainment ticketing across Latin America, successfully closed its initial public offering of 1,875,000 shares priced at $8.00 each, raising $15 million before expenses. The company's shares started trading on the NYSE American on August 7, 2026, under the ticker TP. Ticketp…
Harrow, Inc. announced a 60% sequential and 11% year-over-year revenue increase to $70.7 million in Q2 2026. The company reiterated full-year revenue guidance of $350-$365 million and adjusted EBITDA between $80-$100 million. Key products VEVYE, IHEEZO, and TRIESENCE showed significant unit demand growth. Harrow also launched BYOOVIZ, a retinal bio…
ProKidney Corp. announced completion of enrollment for the Phase 3 PROACT 1 accelerated approval efficacy analysis for their cell therapy rilparencel, targeting chronic kidney disease (CKD) in diabetic patients. The company anticipates topline results in Q2 2027 and remains on track for full enrollment by end of 2026. It appointed Kenneth Locke as …
Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) announced Q2 2026 financial results, highlighting substantial progress toward FDA marketing authorization for its GraftAssureDx transplant diagnostic kit. The FDA completed a key review phase with typical additional information requested, signaling the company is in late-stage review. A favorable Me…
Alumis Inc. reported topline long-term data from its Phase 3 ONWARD3 study for envudeucitinib, an oral TYK2 inhibitor for moderate-to-severe plaque psoriasis, showing 54% of patients achieved complete skin clearance (PASI 100) after 48 weeks. The therapy demonstrated a consistent safety profile with durable efficacy. Alumis plans to submit a New Dr…
Hallador Energy Company reported its Q2 2026 financial and operational results, highlighting progress on the Turtle Creek natural gas generation project with a new budget below $800 million and commercial operation targeted for second half of 2028. Despite a net loss of $15.2 million due to maintenance outages and some unplanned downtime, the compa…
HighPeak Energy, Inc. has announced its financial and operational results for Q2 2026, delivering a 7% production increase above guidance midpoint while maintaining budgeted development costs. The company achieved $82.3 million net income with improved realized prices and operational efficiencies, generating stronger free cash flow and enhancing it…
Definitive Healthcare reported second quarter 2026 financial results with $55.2 million in revenue, representing a 9% decline year-over-year. Despite this decrease, adjusted net income stood at $7.5 million, and adjusted EBITDA was $14.6 million or 26% of revenue. The company highlighted two consecutive quarters of improved net dollar retention and…
James River Group Holdings, Inc. announced its financial results for Q2 2026, highlighting a 59% increase in net income available to common shareholders compared to the same period in 2025. The company focused on disciplined capital deployment, expense reduction, and improving premium retention, especially in the Excess and Surplus Lines segment. D…
Navitas Semiconductor has filed a patent infringement lawsuit against Renesas Electronics alleging that Renesas' GaN power semiconductor products infringe on Navitas' patented technology. The lawsuit highlights Navitas' leadership and innovation in GaN and SiC power semiconductors, used in AI data centers, energy grids, and industrial electrificati…
RUM Group Inc. reported record Q2 2026 results with revenue reaching $40.4 million, up 61% year-over-year. The company completed the acquisition of Northern Data AG, significantly expanding its AI infrastructure with 250MW of unmonetized GPU capacity. RUM Group has introduced formal revenue guidance for Q3 2026 between $87 million and $93 million, …
Damora Therapeutics initiated the Phase 1/1b clinical trial of its lead candidate DMR-001 targeting mutant calreticulin-driven blood disorders, presenting strong preclinical data at EHA 2026. The company enhanced its governance by adding Dr. Andrew Cheng to the board, and maintains a robust cash position of $540.5 million, funding operations into l…
Annexon, Inc., a Nasdaq-listed biopharmaceutical company focused on targeted immunotherapies for neuroinflammatory diseases, announced the appointment of Dr. Mark S. Blumenkranz to its board of directors. Dr. Blumenkranz is a renowned retinal specialist and experienced biotech entrepreneur whose expertise is expected to support the commercializatio…
Fractyl Health announced robust one-year data from its REMAIN-1 and REVEAL-1 cohorts showing durable, drug-free weight maintenance after a single Revita procedure, significantly outperforming sham controls. The company reaffirmed its 2026 milestones including pivotal trial data readout in Q4 and potential FDA De Novo submission. Financial results s…
Metagenomi Therapeutics disclosed its second quarter 2026 financial results and business updates, highlighting ongoing progress toward submitting the investigational new drug (IND) application for its lead genome editing program MGX-001 aimed at treating hemophilia A. The company maintains a strong cash position of $120.7 million to support operati…
